Search

everythinglearnresearchcommunity

for

Search:↓

Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.

About half of people with mild alopecia areata see hair regrowth in a year, but relapses are common.

Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Trichoscopy shows black dots, yellow dots, and empty follicles are common in Alopecia Areata, with broken and exclamation mark hair as typical patterns.

Alopecia areata mainly affects young people, often showing as patchy hair loss on the scalp.

Low serum ferritin levels are linked to more severe and longer-lasting alopecia areata in children.

Alopecia areata in children shows varied forms and treatment challenges, with some achieving full or partial hair regrowth.

A man had an unusual type of hair loss that didn't match known patterns and didn't improve with treatment.

Most children with alopecia areata have patchy hair loss and common trichoscopic features like yellow and black dots.

Platelet-rich plasma (PRP) injections successfully treated a woman's steroid-resistant hair loss, causing hair to regrow within a month.

Microneedling with triamcinolone helps hair regrowth in ophiasis alopecia areata.

Early recognition and treatment of atypical alopecia areata in infants are crucial.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Trichoscopy helps diagnose frontal fibrosing alopecia, even with unusual patterns.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

Both cryotherapy and FCO2 laser are effective and safe for treating patchy alopecia areata.

Certain factors like patchy hair loss at the back of the head, being female, and younger age at diagnosis can lead to a worse outcome for alopecia areata.

Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.

A woman's hair grew back after stopping acitretin for psoriasis and getting steroid treatment, and low vitamin D might be linked to alopecia severity.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.

There's no strong link between Alopecia Areata, a hair loss condition, and fatty liver, but more research is needed.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.